Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
17.59
+0.17 (0.98%)
At close: Jan 21, 2026, 4:00 PM EST
17.45
-0.14 (-0.80%)
After-hours: Jan 21, 2026, 5:04 PM EST
Alto Neuroscience Employees
Alto Neuroscience had 76 employees as of December 31, 2024.
Employees
76
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$819,171
Market Cap
546.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Keros Therapeutics | 169 |
| Alpha Tau Medical | 125 |
| Kyverna Therapeutics | 112 |
| Verastem | 78 |
| Lexeo Therapeutics | 72 |
| CorMedix | 65 |
| Design Therapeutics | 54 |
ANRO News
- 7 days ago - Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression - Business Wire
- 8 days ago - Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology - Business Wire
- 7 weeks ago - Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Business Wire
- 7 weeks ago - Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 - Seeking Alpha
- 2 months ago - Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 3 months ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Alto Neuroscience Announces $50 Million Private Placement Financing - Business Wire
- 3 months ago - Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting - Business Wire